The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Cited by
Sorted by citations
Items 601–700 of 1,001
Dong, Y., He, Q., Pei, L., Yang, M., Huang, L., Kong, J., He, W., Liu, H., Xu, S., Qin, H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06000-x · Cited by 21
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Tian, Y., Seifermann, M., Bauer, L., Luchena, C., Wiedmann, J. J., Schmidt, S., Geisel, A., Afonin, S., Höpfner, J., Brehm, M., et al. (2024) · Small · doi:10.1002/smll.202307215 · Cited by 20
Application of PROTACs in target identification and validation
Liu, Y., Liang, J. Y., Zhu, R., Yang, Y., Wang, Y., Wei, W., Li, H., & Chen, L. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0010 · Cited by 21
Cheng, S., Feng, Y., Li, W., Liu, T., Lv, X., Tong, X., Xi, G., Ye, X., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116629 · Cited by 20
Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6
Xiao, Y., & Zhang, X. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0023 · Cited by 20
Lin, W., Li, Y., Yang, L., & Chen, T. (2020) · ACS Omega · doi:10.1021/acsomega.0c05221 · Cited by 20
Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors
Fu, Z., Yang, C., Yang, Y., Pan, M., Hou, H., & Li, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.020 · Cited by 20
Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.048 · Cited by 19
A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase
Ruan, J., Liang, D., Yan, W., Zhong, Y., Talley, D. C., Rai, G., Tao, D., LeClair, C. A., Simeonov, A. M., Zhang, Y., et al. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e22-06-0233 · Cited by 19
HiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degrader Development
Tsang, T., Huerta, F., Liu, Y., Che, J., Metivier, R. J., Ferrao, S., Donovan, K. A., Jones, L. H., Zerfas, B. L., & Nowak, R. P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00084 · Cited by 19
Xue, W., Li, T., Gu, Y., Li, S., & Xia, N. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2227699 · Cited by 19
A Degron Blocking Strategy Towards Improved CRL4 CRBN Recruiting PROTAC Selectivity**
Bouguenina, H., Scarpino, A., O’Hanlon, J. A., Warne, J. M., Wang, H., Hak, L. C. W., Sadok, A., McAndrew, C., Stubbs, M., Pierrat, O. A., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300351 · Cited by 19
Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities
Dang, X., Duan, J., Ye, E., Mao, N.-D., Bai, R., Zhou, X., & Ye, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106934 · Cited by 19
Tian, L., Qiang, T., Yang, X., Yue, G., Zhai, X., Kang, K., Du, C., Lu, Q., Gao, H., Zhang, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115979 · Cited by 19
Small molecules modulating RNA splicing: a review of targets and future perspectives
Bouton, L., Ecoutin, A., Malard, F., & Campagne, S. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00685a · Cited by 19
Jackson, C., & Beveridge, R. (2024) · The Analyst · doi:10.1039/d4an00110a · Cited by 19
Qiu, Y., Wiewiora, R., Izaguirre, J. A., Xu, H., Sherman, W., Tang, W., & Huang, X. (2024) · JACS Au · doi:10.1021/jacsau.4c00503 · Cited by 20
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 19
The “three body solution”: Structural insights into molecular glues
Tomlinson, A. C. A., Knox, J. E., Brunsveld, L., Ottmann, C., & Yano, J. K. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103007 · Cited by 20
Pan, B., Mountford, S. J., Kiso, M., Anderson, D. E., Papadakis, G., Jarman, K. E., Tilmanis, D., Maher, B. M., Tran, T., Shortt, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00863-1 · Cited by 19
The Present and Future of Novel Protein Degradation Technology
Xia, L., Liu, W., Song, Y., Zhu, H., & Duan, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011162955 · Cited by 19
Targeted protein modification as a paradigm shift in drug discovery
Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18
Kudo, G., Hirao, T., Harada, R., Shigeta, Y., Hirokawa, T., & Yoshino, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00102 · Cited by 18
Lysosome-targeting chimeras enable targeted protein degradation
Li, B., Li, Y., Zhang, J. J., Badama, S., Zhao, X., Wang, L., Zhang, T. W., Wang, X., Yi, X., Ding, G., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.01.008 · Cited by 19
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
Peng, W., Pan, X., Wang, S., Huang, G., & Qian, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03330 · Cited by 19
Conformational Dynamics and Binding Kinetics Drive Mutant Selective Degradation of EGFR
Rosenberg, S., Shanahan, F., Yamazoe, S., Kschonsak, M., Zeng, Y. J., Lee, J., Plise, E. G., Yen, I., Rose, C. M., Quinn, J. G., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2023.01.007 · Cited by 18
Breaking free from the crystal lattice: Structural biology in solution to study protein degraders
Haubrich, K., Spiteri, V. A., Farnaby, W., Sobott, F., & Ciulli, A. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102534 · Cited by 19
Self-citationHuang, J., Ma, Z., Peng, X., Yang, Z., Wu, Y., Zhong, G., Ouyang, T., Chen, Z., Liu, Y., Wang, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01414 · Cited by 18
Diehl, C. J., Salerno, A., & Ciulli, A. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202319456 · Cited by 18
Self-citationZaman, S. U., Pagare, P. P., Huang, B., Rilee, G. J., Ma, Z., Zhang, Y., & Li, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107613 · Cited by 18
German, B., Alaiwi, S. A., Ho, K.-L., Nanda, J. S., Fonseca, M. A., Burkhart, D. L., Sheahan, A. V., Bergom, H. E., Morel, K. L., Beltran, H., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0069 · Cited by 18
Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B. E., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01130 · Cited by 19
AI-DPAPT: a machine learning framework for predicting PROTAC activity
Abouzied, A. S., Alshammari, B., Kari, H., Huwaimel, B., Alqarni, S., & Kassab, S. E. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11011-7 · Cited by 18
Liang, J.-J., Xie, H., Yang, R., Wang, N., Zheng, Z., Zhou, C., Wang, Y., Wang, Z., Liu, H., Shan, L., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116331 · Cited by 18
Wang, X., Wang, Q., Ran, K., Ren, J., Shi, Y., & Yu, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105238 · Cited by 18
Cooperativity as quantification and optimization paradigm for nuclear receptor modulators
de Vink, P. J., Koops, A. A., D’Arrigo, G., Cruciani, G., Spyrakis, F., & Brunsveld, L. (2022) · Chemical Science · doi:10.1039/d1sc06426f · Cited by 19
Zhao, Y., Guan, Y., Zhao, F., Yu, T., Zhang, S., Zhang, Y., Duan, Y., & Zhou, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114144 · Cited by 19
Chen, J., He, H., Wei, A., Li, Y., Cheng, G., Qin, H., Zhong, H., Liu, H., Geng, M., Shen, A., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114259 · Cited by 18
Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1
Zhou, Q., Wu, W., Jia, K., Qi, G., Sun, X. S., & Li, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114830 · Cited by 18
Su, W., Tan, M., Wang, Z., Zhang, J., Huang, W., Song, H., Wang, X., Ran, H., Gao, Y., Nie, G., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202218128 · Cited by 18
Targeting TAK1: Evolution of inhibitors, challenges, and future directions
Benedik, N. S., Proj, M., Steinebach, C., Sova, M., & Sosič, I. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108810 · Cited by 17
Xiao, Z., Gavriil, E.-S., Cao, F., Zhang, X., Li, S. X., Kotelnikov, S., Michalska, P., Marte, F., Huang, C., Lu, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01420 · Cited by 17
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 17
Self-citationHijacking ERAD for targeted degradation of transmembrane proteins
Song, H., Wang, W., Mei, T., Zheng, H., Ning, K., Liu, X., Cheung, S., Cao, Z., Sheng, D., Mai, X., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.018 · Cited by 17
Recent advances of PROTACs technology in neurodegenerative diseases
Wang, C., Zhang, Y., Yang, S., & Xing, D. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105015 · Cited by 17
Development of a highly potent and selective degrader of LRRK2
Hatcher, J. M., Zwirek, M., Sarhan, A. R., Vatsan, P. S., Tonelli, F., Alessi, D. R., Davies, P., & Gray, N. S. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129449 · Cited by 17
Kinetic Modeling of PROTAC‐Induced Protein Degradation
Zhao, H., & Narjes, F. (2023) · ChemMedChem · doi:10.1002/cmdc.202300530 · Cited by 18
Urbina, A., Hallatt, A. J., Robertson, J., & Ciulli, A. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446232 · Cited by 17
Self-citationZhou, Q., Wang, W., & Deng, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04838-0 · Cited by 18
Nassar, H., Sarnow, A., Celik, I., Abdelsalam, M. A. M., Robaa, D., & Sippl, W. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202500102 · Cited by 17
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 17
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
Liu, S., Da, Y., Wang, F., Yan, R., Shu, Y., Lin, P., & Lin, J. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02526-3 · Cited by 17
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
Vieux, E. F., Agafonov, R. V., Emerson, L., Isasa, M., Deibler, R. W., Simard, J. R., Cocozziello, D., Ladd, B., Lee, L., Li, H., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000673 · Cited by 17
Reinforcement Learning-Driven Linker Design via Fast Attention-based Point Cloud AlignmentPreprint
Neeser, R. M., Akdel, M., Kovtun, D., & Naef, L. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2306.08166 · Cited by 17
PRosettaC outperforms AlphaFold3 for modeling PROTAC ternary complexes
Schulz, J. M., Schürer, S. I., Reynolds, R. C., & Schürer, S. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-21502-8 · Cited by 16
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation
Zheng, Y., Singh, A., Niu, Z., Marin, V. L., Young, J., Richardson, P. L., Hemshorn, M. L., Cooley, R. B., Karplus, P. A., Puvar, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02741 · Cited by 16
Weldert, A. C., Frey, A. F., Krone, M. W., Krähe, F., Kuhn, H., Kersten, C., & Barthels, F. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00359h · Cited by 16
Stevens‐Cullinane, L., Rees, T. W., Evans, C., Ho, P., Kintzel, M., Yip, Y. M., Jia, R., Bailey, J., Clifford, E., Alam, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c12405 · Cited by 17
Kaji, T., Koga, H., Kuroha, M., Akimoto, T., & Hayata, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-59966-5 · Cited by 16
Synthesis and Evaluation of Cereblon‐Recruiting HaloPROTACs
Ody, B. K., Zhang, J., Nelson, S. E., Xie, Y., Liu, R., Dodd, C. J., Jacobs, S. E., Whitzel, S. L., Williams, L. A., Gozem, S., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300498 · Cited by 16
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
Ding, Y., Xing, D., Fei, Y., Luo, S., & Lu, B. (2024) · Medicine Plus · doi:10.1016/j.medp.2023.100004 · Cited by 16
Medicinal chemistry insights into PRMT5 inhibitors
Jiao, Z., Huang, Y., Gong, K., Liu, Y., Sun, J., Yu, S., & Zhao, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107859 · Cited by 17
A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death
Nix, M. N., Gourisankar, S. P., Bowman, K., Nettles, S. A., Yang, H. H., Dwyer, B. G., Sarott, R. C., Abuzaid, H. Z., Martinez, M. M., Phillips, N. A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.06.037 · Cited by 16
Primed for degradation: How weak protein interactions enable molecular glue degraders
Hanzl, A., Inghelram, C., Schmitt, S., & Thomä, N. H. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103052 · Cited by 17
In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
Tomoshige, S., & Ishikawa, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116221 · Cited by 17
Zhai, J., Li, C., Sun, B., Wang, S., Cui, Y., Gao, Q., & Sang, F. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129041 · Cited by 16
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Mandl, A., Markowski, M. C., Carducci, M. A., & Antonarakis, E. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2186851 · Cited by 16
Bromodomain-Containing Protein 4: A Druggable Target
Shi, Y., Liu, J., Zhao, Y., Cao, J., Li, Y., & Guo, F. (2019) · Current Drug Targets · doi:10.2174/1574885514666190618113519 · Cited by 16
Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation
Spiteri, V. A., Segal, D., Correa-Sáez, A., Iso, K., Casement, R., Ordoño, M. M. I., Nakasone, M. A., Sathe, G. J., Schätz, C., Peters, H. E., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02224-y · Cited by 16
Self-citationFunctional mapping of the 14-3-3 hub protein as a guide to design 14-3-3 molecular glues
Somsen, B. A., Craenmehr, F. W. B., Liu, W.-H. W., Koops, A. A., Pennings, M. A. M., Visser, E. J., Ottmann, C., Cossar, P. J., & Brunsveld, L. (2022) · Chemical Science · doi:10.1039/d2sc04662h · Cited by 15
Sciaccotta, R., Gangemi, S., Penna, G., Giordano, L., Pioggia, G., & Allegra, A. (2024) · Antioxidants · doi:10.3390/antiox13040475 · Cited by 15
Zhang, H., Zhang, Y., Feng, Z., Shuai, M., Ma, X., Wang, S., Yu, S., Deng, R., Luo, D., Shi, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02259 · Cited by 15
Quantitative Measurement of Rate of Targeted Protein Degradation
Lynch, T. L., Marin, V. L., McClure, R. A., Phipps, C. J., Ronau, J. A., Rouhimoghadam, M., Adams, A. M., Kandi, S., Wolke, M. L., Shergalis, A. G., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00262 · Cited by 16
Zaman, S. U., Pagare, P. P., Ma, H., Hoyle, R. G., Zhang, Y., & Li, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00122b · Cited by 15
Schwalm, M. P., Menge, A., Elson, L., Greco, F., Robers, M. B., Müller, S., & Knapp, S. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00450 · Cited by 15
Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader
Zhong, Y., Kim, H., Qian, C., Xie, L., Chen, X., Xiong, Y., Hu, J., Chen, M., Guccione, E., Shen, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00198 · Cited by 15
Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Qi, J., & Zhang, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0557 · Cited by 15
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Min, J., Mayasundari, A., Keramatnia, F., Jonchère, B., Yang, S. W., Jarusiewicz, J., Actis, M., Das, S., Young, B. M., Slavish, J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202108848 · Cited by 15
Ma, L., Li, G. L., Yang, T., Zhang, L., Wang, X., Xu, X., & Ni, H. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04483-7 · Cited by 15
Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M. M., Birge, R. B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135373 · Cited by 15
MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug Development
Bartoschik, T., Zoephel, A., Rumpel, K., Ciulli, A., & Heffern, C. T. R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_6 · Cited by 15
Self-citationDegradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity
Grigglestone, C. E., & Yeung, K. S. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00543 · Cited by 15
Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation
Hakem, F. T., Abdelwaly, A., Alshaman, R., Alattar, A., Alanazi, F. E., Zaitone, S. A., & Helal, M. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091160 · Cited by 14
Li, D., Liang, H., Wei, Y., Xiao, H., Peng, X., & Pan, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115999 · Cited by 14
Targeted degradation of specific TEAD paralogs by small molecule degraders
Chen, H., Gridnev, A., Schlamowitz, N. S., Hu, W., Dey, K., Zheng, G., & Misra, J. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37829 · Cited by 14
Quantifying Cooperativity through Binding Free Energies in Molecular Glue Degraders
Dudás, B., Athanasiou, C., Mobarec, J. C., & Rosta, E. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c00064 · Cited by 14
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
Delport, A., & Hewer, R. (2019) · Molecules · doi:10.3390/molecules24183272 · Cited by 14
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14
Expression and purification of functional recombinant CUL2•RBX1 from E. coli
Diaz, S., Li, L., Wang, K., & Liu, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-90770-x · Cited by 14
Methods for Quantitative Assessment of Protein Degradation
Nowak, R. P., Yue, H., Park, E. Y., & Fischer, E. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_13 · Cited by 14
Pedrucci, F., Pappalardo, C., Marzaro, G., Ferri, N., Ferlin, A., & Toni, L. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126630 · Cited by 14
Applications and Limitations of Oxime‐Linked “Split PROTACs”
Gui, W., & Kodadek, T. J. (2022) · ChemBioChem · doi:10.1002/cbic.202200275 · Cited by 14
Yan, Z., Lyu, X., Lin, D., Wu, G., Gong, Y., Ren, X., Xiao, J., Lou, J., Huang, H., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115381 · Cited by 14
Danazumi, A. U., Ishmam, I. T., Idris, S., Izert, M. A., Balogun, E. O., & Górna, M. W. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106451 · Cited by 14
Ayinde, O. R., Sharpe, C., Stahl, E. H., Tokarski, R. J., Lerma, J. R., Muthusamy, N., Byrd, J. C., & Fuchs, J. R. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00082 · Cited by 14
Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras
Jia, Q., Zhang, Y., Liu, F., Dong, W., Zhu, L., Wang, F., & Jiang, J. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01236 · Cited by 14
Design and Synthesis of Anti-Cancer Chimera Molecules Based on Marine Natural Products
Ha, M. W., Song, B. R., Chung, H. J., & Paek, S. (2019) · Marine Drugs · doi:10.3390/md17090500 · Cited by 14
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 14
Programmable PROTAC delivery for precise and spatiotemporal protein degradation
Sheng, J., Ma, T., Wu, Y., & Wang, M. (2026) · Chemical Communications · doi:10.1039/d5cc05651a · Cited by 13
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
